Search

Your search keyword '"Quartier A"' showing total 10,046 results

Search Constraints

Start Over You searched for: Author "Quartier A" Remove constraint Author: "Quartier A"
10,046 results on '"Quartier A"'

Search Results

Catalog

Books, media, physical & digital resources

3. Hereditary C1q Deficiency is Associated with Type 1 Interferon-Pathway Activation and a High Risk of Central Nervous System Inflammation

7. Incidence and risk factors for thromboembolic events in pediatric-onset inflammatory bowel disease: A French population-based study

8. Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based studyResearch in context

10. Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome

11. Molecular consequences of PQBP1 deficiency, involved in the X-linked Renpenning syndrome

14. Unlocking biomedical data sharing: A structured approach with digital twins and artificial intelligence (AI) for open health sciences

15. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe

16. Clinical spectrum and outcome of Takayasu's arteritis in children

17. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

18. On Inhabiting Monastic Heritage: Monastery 'Nieuw Sion' in the Netherlands as Material Burden and Spiritual Opportunity

20. Strategies for mainstreaming nature-based solutions in urban governance capacities in ten European cities

23. Early systemic inflammation induces neurodevelopmental disorders: results from ARTEMIS, a French multicenter study of juvenile rheumatisms and systemic autoimmune and auto-inflammatory disorders and meta-analysis

26. Pathogenic variants in the NLRP3 LRR domain at position 861 are responsible for a boost-dependent atypical CAPS phenotype

28. French recommendations for the management of non-infectious chronic uveitis

29. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome

30. An integrated process for planning, delivery, and stewardship of urban nature-based solutions: The Connecting Nature Framework

31. Data Stewardship – Austrian National Strategy and Alignment

32. Fostering Open Data Practices in Research-Performing Organizations

36. The role of artificial intelligence and machine learning in harmonization of high-resolution post-mortem MRI (virtopsy) with respect to brain microstructure

37. Systemic juvenile idiopathic arthritis in French Afro-Caribbean children, a retrospective cohort study

38. mTORC1 links pathology in experimental models of Still’s disease and macrophage activation syndrome

39. Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis

40. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry

41. Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients From the JIR Cohort.

42. On Inhabiting Monastic Heritage: Monastery "Nieuw Sion" in the Netherlands as Material Burden and Spiritual Opportunity.

43. Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study.

44. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study

46. A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report

47. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)

49. Mutations in DCC cause isolated agenesis of the corpus callosum with incomplete penetrance

50. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study